北京市春立正達醫療器械股份有限公司
Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

2025 THIRD QUARTERLY REPORT

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) to provide shareholders of the Company and the public with the updated financial information of the Company. This announcement is also published on the website of the Shanghai Stock Exchange simultaneously.

The unaudited results (the "**Third Quarterly Report**") of the Group for the nine months ended 30 September 2025 are provided. The financial information contained in the Third Quarterly Report was prepared in accordance with the Chinese Accounting Standards for Business Enterprises ("**CASs**"), and consists accounting data which has not been audited. Potential investors and shareholders of the Company are advised to pay attention to the underlying investment risks.

The Third Quarterly Report is written in both Chinese and English. In the case of any discrepancies, the Chinese version of the Third Quarterly Report shall prevail.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Chairman
Shi Wenling

Beijing, the PRC, 30 October 2025

As at the date of this announcement, the executive Directors are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director is Mr. Wang Xin; and the independent non-executive Directors are Ms. Xu Hong, Mr. Weng Jie and Mr. Wong Tak Shing.

* *For identification purposes only*

Securities Code: 688236 Stock Short Name: Chunli Medical

H Share Securities Code: 01858

Beijing Chunlizhengda Medical Instruments Co., Ltd.*
2025 Third Quarterly Report

The Board of Directors of the Company and all Directors undertake that this announcement contains no false record, misleading statement or material omission, and assume legal responsibility for the truthfulness, accuracy and completeness of its contents in accordance with law.

Important Notice:

The Board of Directors of the Company, the Board of Supervisors, the Directors, Supervisors, senior management warrant that the content of this quarterly report is true, accurate and complete and contains no false record, misleading statement or material omission, and jointly and severally assume legal responsibility for the content of this report.

The person in charge of the Company, the person in charge for accounting affairs of the Company and the person in charge of the accounting department (financial controller) warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.

Whether the financial statements for the third quarter are audited?
□Yes √No

1. Key financial data

(A) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

Item	Reporting Period	Percentage change of the Reporting Period as compared to the corresponding period of last year (%)	From the beginning of the year to the end of the Reporting Period	Percentage change from the beginning of the year to the end of Reporting Period compared to the corresponding period of last year (%)
Revenue	268,497,491.74	109.51	756,093,897.40	48.75
Gross profit	84,476,176.70	N/A	211,788,696.95	220.09
Net profit attributable to the shareholders of the listed company	77,061,913.60	N/A	191,531,404.47	213.21
Net profit attributable to the shareholders of the listed company after deducting non-recurring profit or loss	74,518,597.99	N/A	180,704,056.22	311.07
Net cash flows generated from operating activities	N/A	N/A	174,567,044.11	N/A
Basic earnings per share (RMB/share)	0.20	N/A	0.50	212.50
Diluted earnings per share (RMB/share)	0.20	N/A	0.50	212.50
Weighted average RONA (%)	2.62	N/A	6.60	Increase by 4.46 percentage points
Total investments in research and development	35,618,326.74	11.25	86,472,598.27	-13.25
Percentage of research and development investment to revenue (%)	13.27	Decrease by 11.71 percentage points	11.44	Decrease by 8.17 percentage points
	At the end of the Reporting Period	At the end of last year		Percentage change at the end of the Reporting

			Period as compared to the end of last year (%)
Total assets	3,540,324,901.27	3,465,734,982.98	2.15
Owners' equity attributable to the shareholders of the listed company	2,984,717,139.32	2,819,902,283.28	5.84

Note: The "Reporting Period" refers to the three-month period from the beginning to the end of the current quarter as the same below.

(B) Non-recurring profit or loss items and amounts

√Applicable □Non applicable

Unit: Yuan Currency: RMB

Non-recurring gain or loss item	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period	Description
Gain and loss from disposal of non-current assets, including write-off of provision for asset impairment		3,848.03	
Government grants included in profit or loss for the current period, excluding government grants that are closely related to the normal operation of the Company, complying with the requirements of national policy, entitled as per the standard established, and those that have continuous effect to the profit and loss of the Company	119,807.97	1,853,082.97	
Except for effective hedging business conducted in the ordinary course of business of the Company, gain or loss arising from change in fair value of financial assets held by and financial liabilities arising from non-financial enterprises, and gain or loss arising from disposal of financial assets and financial liabilities	2,782,684.93	10,295,963.83	

Other non-operating income and expenses other than aforesaid items	61,464.54	60,765.38	
Other gain or loss items within the definition of non-recurring profit or loss		483,685.50	
Less: Effect of income tax	420,641.83	1,861,054.76	
Impact of minority interests (after tax)		8,942.70	
Total	2,543,315.61	10,827,348.25	

Reasons should be given for the Company defining the non-recurring gain or loss items with significant amount not set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public – Non-recurring Gain or Loss along with non-recurring gain or loss items set out in the Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Securities to the Public – Non-recurring Gain or Loss as recurring gain or loss items.

√Applicable □Not applicable

Unit: Yuan Currency: RMB

Item	Amount involved	Reason(s)
Additional deduction of value-added tax for advanced manufacturing industry	1,219,703.64	Continuous impact on gains or losses of the Company
Government grants related to assets	3,352,983.84	Continuous impact on gains or losses of the Company

(C) Description of and reasons for the changes in key accounting data and financial indicators

√Applicable □Not applicable

Item	Change percentage (%)	Main reason(s)
Revenue for the Reporting Period	109.51	It is mainly due to the fact that the product lines of the Company have gradually entered into a new growth normality upon being included in the centralized procurement. The Company consistently adheres to a two-wheel drive strategy of product innovation and international development, and promotes the sustained, steady and healthy development of various businesses. On the other hand, through the refined operational management, optimized resource allocation and other initiatives, the Company has further released its potential for profit growth, and injected strong momentum into overall business performance.
Revenue from the beginning of the year to the end of the Reporting Period	48.75	
Gross profit	220.09	
Net profit attributable to the shareholders of the listed company	213.21	
Net profit attributable to the shareholders of the listed company after deducting non-recurring gain or loss	311.07	

Net cash flows generated from operating activities	N/A	It was mainly due to the increased cash received for sales of goods, coupled with the Company's commitment to refined operational management and the decreased operating expenses during the Reporting Period.
Basic earnings per share (RMB/share)	212.50	The increase in net profit during the Reporting Period led to a corresponding increase in its related financial indicators.
Diluted earnings per share (RMB/share)	212.50	

2. Information of shareholders

(A) Total number of ordinary shareholders, number of preferred shareholders with voting rights reinstated, and the shareholding of top ten shareholders

Unit: Share

<table>
<tr><td colspan="2">Total number of ordinary shareholders at the end of the Reporting Period</td><td colspan="3">6,164</td><td colspan="2">Total number of shareholders of preferred shares with voting rights reinstated (if any) at the end of the Reporting Period</td><td colspan="2">0</td></tr>
<tr><td colspan="9">Shareholding of top ten shareholders (excluding lending shares through securities financing)</td></tr>
<tr><td rowspan="2">Name of shareholder</td><td rowspan="2">Nature of shareholder</td><td rowspan="2">Number of shares held</td><td rowspan="2">Shareholding percentage (%)</td><td rowspan="2">Number of shares held subject to trading restrictions</td><td rowspan="2">Number of Shares subject to trading restrictions that include lending shares through securities financing</td><td colspan="2">Shares charged, tagged or frozen</td></tr>
<tr><td>Status of shares</td><td>Number</td></tr>
<tr><td>Shi Chunbao</td><td>Domestic natural person</td><td>120,209,043</td><td>31.34</td><td>-</td><td>-</td><td>None</td><td>0</td></tr>
</table>

Yue Shujun	Domestic natural person	95,447,900	24.88	-	-	None	0
Beijing Panmao Investment Management Co., Ltd. – Panmao (Shanghai) Investment Center (LLP) (北京磐茂投資管理有限公司－磐茂（上海）投資中心（有限合夥）)	Others	17,250,000	4.50	-	-	Unknown	-
Hong Kong Securities Clearing Company Limited	Others	2,958,538	0.77	-	-	Unknown	-
Hua Xia Bank Co., Limited –Zhongou Jingqi Selection Mixed Securities Investment Fund (華夏銀行股份有限公司－中歐景氣精選混合型證券投資基金)	Others	2,832,601	0.74	-	-	Unknown	-
Huang Dong	Domestic natural person	2,533,335	0.66	-	-	Unknown	-
Beijing Panmao Investment Management Co., Ltd. – Panxin (Shanghai) Investment Center (LLP) (北京磐茂投資管理有限公司－磐信（上海）投資中心（有限合夥）)	Others	2,500,000	0.65	-	-	Unknown	-
Agricultural Bank of China Limited – Ping An Low Carbon Economy Hybrid Securities Investment Fund (平安低碳經濟混合型證券投資基金)	Others	2,100,000	0.55	-	-	Unknown	-

Huatai Securities (Shanghai) Asset Management Co., Ltd. (華泰證券資管) – Bank of China – Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board (華泰春立醫療家園 1 號科創板員工持股集合資產管理計劃)	Others	1,660,782	0.43	-	-	Unknown	-
Securities Account Designated for the Repurchase of Beijing Chunlizhengda Medical Instruments Co., Ltd.	Others	1,376,851	0.36	-	-	Unknown	-

Shareholding of top ten shareholders not subject to trading restrictions (excluding lending shares through securities financing)			
Name of shareholder	Number of tradable shares held not subject to trading restrictions	Share class and number	
		Share class	Number
Shi Chunbao	120,209,043	RMB-denominated ordinary shares	120,209,043
Yue Shujun	95,447,900	RMB-denominated ordinary shares	95,447,900
Beijing Panmao Investment Management Co., Ltd. – Panmao (Shanghai) Investment Center (LLP) (北京磐茂投資管理有限公司－磐茂（上海）投資中心（有限合夥）)	17,250,000	RMB-denominated ordinary shares	17,250,000
Hong Kong Securities Clearing Company Limited	2,958,538	RMB-denominated ordinary shares	2,958,538

Hua Xia Bank Co., Limited –Zhongou Jingqi Selection Mixed Securities Investment Fund (華夏銀行股份有限公司－中歐景氣精選混合型證券投資基金)	2,832,601	RMB-denominated ordinary shares	2,832,601
Huang Dong	2,533,335	RMB-denominated ordinary shares	2,533,335
Beijing Panmao Investment Management Co., Ltd. – Panxin (Shanghai) Investment Center (LLP) (北京磐茂投資管理有限公司－磐信（上海）投資中心（有限合夥）)	2,500,000	RMB-denominated ordinary shares	2,500,000
Agricultural Bank of China Limited – Ping An Low Carbon Economy Hybrid Securities Investment Fund (平安低碳經濟混合型證券投資基金)	2,100,000	RMB-denominated ordinary shares	2,100,000
Huatai Securities (Shanghai) Asset Management Co., Ltd. (華泰證券資管) – Bank of China – Huatai Chunli Medical Family No. 1 the collective asset management plan for the shareholding of staff on Technology Innovation Board (華泰春立醫療家園 1 號科創板員工持股集合資產管理計劃)	1,660,782	RMB-denominated ordinary shares	1,660,782
Securities Account Designated for the Repurchase of Beijing Chunlizhengda Medical Instruments Co., Ltd.	1,376,851	RMB-denominated ordinary shares	1,376,851

Description of connected relationship or acting in concert of the above shareholders	1. As of the date of this announcement, Shi Chunbao and Yue Shujun are couple while Panmao and Panxin belong to the same controlling party. Apart from the above, the Company does not receive any statement from the top ten shareholders regarding the existence of connected relationship or agreement of acting-in concert; 2. The Company is not aware of the existence of connected relationship among shareholders of tradable shares, or if they are the concerted parties under the stipulation of Measures for the Administration of Disclosure of Shareholder Equity Changes of Listed Companies.
Description on participation in margin financing and securities lending and lending shares for securities financing by top ten shareholders and top ten shareholders not subject to trading restrictions (if any)	None

As of the end of the Reporting Period, the total number of ordinary shareholders of the Company amounted to 6,164, including 6,149 holders of A Shares and 15 holders of H Shares;

Note: Hong Kong Securities Clearing Company Limited held shares on behalf of customers. As there is no requirements by the relevant rules of the Hong Kong Stock Exchange for customers to declare whether the shares they held got pledged or frozen, Hong Kong Securities Clearing Company Limited is unable to calculate or provide the number of shares pledged or frozen.

The total number of shares held by Mr. Shi Chunbao includes H Shares that are not subject to trading restrictions.

Lending of shares by shareholders involved in the securities financing business holding more than 5% of the shares, top 10 shareholders and top 10 shareholders of tradable shares not subject to trading restrictions

□ Applicable √ Not applicable

The changes of the top 10 shareholders and the top 10 shareholders of tradable shares not subject to trading restrictions resulted from lending/repayment for securities financing compared with the previous period

□ Applicable √ Not applicable

3. Other notice

Other important information related to the operational conditions of the Company during the Reporting Period which requires the attention of the investors

√Applicable □Not applicable

Profit Distribution Plan for the First Three Quarters of 2025

The Company proposes to make a profit distribution for the first three quarters of 2025 on the basis of the total share capital registered on the date of the implementation of the rights registration for the distribution, less the number of shares held by the Company's securities account designated for the repurchase. The profit distribution plan is set out below:

The Company proposes to distribute a cash dividend of RMB2.10 (tax inclusive) for every 10 shares to all shareholders. As of 30 September 2025, the total share capital of the Company was 383,568,500 shares, and after deducting the number of shares held by the A-share repurchase account of 1,376,851 shares, the actual number of shares participating in the profit distribution was 382,191,649 shares, and based on this calculation, a total of RMB80,260,246.29 (tax inclusive) was proposed to be paid out as cash dividend. The amount of cash dividend of the Company accounts for 41.90% of the net profit attributable to ordinary shareholders of the listed company in the consolidated statement. The Company will not carry out any capitalization of capital reserve and distribute bonus shares. The profit distribution plan is subject to the consideration at the 2025 First Extraordinary General Meeting of the Company.

For the details of the cash dividends distribution to H shareholders, please see the circular for the extraordinary general meeting to be published by the Company on the Hong Kong Stock Exchange on the same date as this report.

4. Quarterly financial statements

(A) Type of auditor's opinion

□Applicable √Not applicable

(B) Financial statements

CONSOLIDATED BALANCE SHEET

30 September 2025

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2025	31 December 2024
Current assets:		
Monetary funds	1,109,889,349.24	1,139,778,517.24
Settlement reserve		
Placements with banks and non-bank financial institutions		
Held-for trading financial assets	885,474,630.13	745,797,775.34
Derivative financial assets		
Notes receivable	27,750,461.00	160,052,600.00
Accounts receivable	278,854,169.85	218,658,632.35
Accounts receivable financing		
Prepayment	7,911,932.75	2,993,330.49
Premium receivable		
Reinsurance premium receivables		
Reserves for reinsurance contract receivables		
Other receivables	283,549.87	177,919.45

Including:Interests receivables		
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	568,300,347.01	550,842,677.89
Including: Data resources		
Contract assets		
Assets held for-sale		
Non-current assets due within one year		
Other current assets	22,423,814.82	22,179,673.24
Total current assets	2,900,888,254.67	2,840,481,126.00
Non-current assets:		
Loans and advances		
Debt investments		
Other debt investments		
Long-term receivables		
Long-term equity investments		
Other investments in equity instruments		
Other non-current financial assets		
Investment property		
Fixed assets	312,182,270.18	311,008,174.74
Construction in progress	159,649,971.22	156,777,773.93
Productive biological assets		
Oil & gas assets		
Right-of-use assets	541,163.86	1,017,028.37
Intangible assets	121,664,058.70	127,569,991.24
Including: Data resources		
Development expenditures		
Including: Data resources		
Goodwill		
Long-term prepayments		
Deferred income tax assets	31,229,536.92	26,113,029.08
Other non-current assets	14,169,645.72	2,767,859.62
Total non-current assets	639,436,646.60	625,253,856.98
Total assets	3,540,324,901.27	3,465,734,982.98
Current liabilities:		
Short-term borrowings		
Borrowings from central banks		
Placements from banks and non-bank financial institutions		

Held-for trading financial liabilities		
Derivative financial liabilities		
Notes payable		
Accounts payable	178,184,791.15	227,845,174.60
Advances received		
Contract liabilities	87,435,853.74	128,563,190.58
Financial assets sold under repurchase agreement		
Deposits and placements from peers		
Brokerage for trading securities		
Brokerage for underwriting securities		
Employee remuneration payable	50,211,632.40	52,272,626.41
Taxes payable	22,974,774.01	6,656,073.81
Other payables	63,122,539.31	69,459,231.16
Including: Interests payable		
Dividends payable		
Handling fee and commission payables		
Reinsurance premium payables		
Held-for-sale liabilities		
Non-current liabilities due within one year	140,819.74	682,121.00
Other current liabilities	56,096,864.54	61,266,897.36
Total current liabilities	458,167,274.89	546,745,314.92
Non-current liabilities:		
Reserves for insurance contracts		
Long-term borrowings		
Bonds payable		
Including: Preferred shares		
Perpetual bonds		
Lease liabilities	77,773.71	184,315.07
Long-term payables		
Long-term employee remuneration payable		
Estimated liabilities		
Deferred gains	83,396,575.71	86,749,559.54
Deferred income tax liabilities	12,443,264.73	10,711,656.65
Other non-current liabilities		
Total non-current liabilities	95,917,614.15	97,645,531.26
Total liabilities	554,084,889.04	644,390,846.18

Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	383,568,500.00	383,568,500.00
Other equity instruments		
Including: Preferred shares		
Perpetual bonds		
Capital reserve	1,044,799,419.83	1,044,799,419.83
Less: Treasury shares	20,008,021.82	12,018,864.19
Other comprehensive income		
Specific reserve		
Surplus reserve	195,115,661.94	195,115,661.94
General reserve		
Undistributed profits	1,381,241,579.37	1,208,437,565.70
Total equity attributable to owners (or equity attributable to shareholders) of the parent company	2,984,717,139.32	2,819,902,283.28
Minority interests	1,522,872.91	1,441,853.52
Total owners' equity (or shareholders' equity)	2,986,240,012.23	2,821,344,136.80
Total liabilities and owners' equity (or shareholders' equity)	3,540,324,901.27	3,465,734,982.98

Person in charge of the Company: Shi Wenling; Person in charge for accounting affairs of the Company: Lu Hongyue; Person in charge of the accounting department: Lu Hongyue

Consolidated income statement

January to September 2025

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2025 (January to September)	First three quarters of 2024 (January to September)
1. Total operating revenue	756,093,897.40	508,283,661.62
Including: Operating revenue	756,093,897.40	508,283,661.62
Interest income		
Premiums gained		
Income from handling fee and commission		
2. Total operating cost	515,865,735.32	449,469,327.29
Including: Operating cost	247,450,780.09	156,043,170.05
Interest expense		

Handling fee and commission expense		
Surrender value		
Net amount of compensation payout		
Net amount of insurance contracts reserves withdrawn		
Policy dividend payment		
Reinsurance expenses		
Taxes and surcharge	6,867,479.82	6,012,961.59
Selling expenses	146,195,182.01	163,464,944.14
Administrative expenses	38,603,081.68	31,357,332.90
Research and development expenses	86,472,598.27	99,676,406.70
Financial expenses	-9,723,386.55	-7,085,488.09
Including: Interest expenses	14,188.80	27,847.25
Interest income	10,658,846.31	8,960,596.25
Add: Other gains	6,909,455.54	7,865,268.90
Investment income (losses are presented as “–”)	3,217,026.86	9,122,896.79
Including: Investment income from associates and joint ventures		
Gains from derecognisation of financial assets measured at amortised cost		
Foreign exchange gains (losses are presented as “–”)		
Net profit on hedging exposure (losses are presented as “–”)		
Gains on changes of fair value (losses are presented as “–”)	7,078,936.97	6,079,575.33
Loss on credit impairment (losses are presented as “–”)	-13,646,674.50	-7,060,926.86
Loss on asset impairment (losses are presented as “–”)	-32,062,823.41	-9,409,707.93
Gains on disposal of assets (losses are presented as “–”)	3,848.03	39,213.61
3. Operating profit (losses are presented as “–”)	211,727,931.57	65,450,654.17
Add: Non-operating income	195,880.52	870,286.20
Less: Non-operating expenses	135,115.14	156,306.21
4. Gross profit (total losses are presented as “–”)	211,788,696.95	66,164,634.16

Less: income tax expenses	20,176,273.09	5,155,985.69
5. Net profit (net losses are presented as "–")	191,612,423.86	61,008,648.47
(A) Classified by continuity of operation		
1. Net profit for continuing operation (net losses are presented as "–")	191,612,423.86	61,008,648.47
2. Net profit for ceased operation (net losses are presented as "–")		
(B) Classified by ownership		
1. Net profit attributable to the shareholders of the parent company (net losses are presented as "–")	191,531,404.47	61,151,445.55
2. Non-controlling shareholders' profit or loss (net losses are presented as "–")	81,019.39	-142,797.08
6. Net other comprehensive income after tax		
(I) Net other comprehensive income after tax attributable to the owners of the parent company		
1. Other comprehensive income that cannot be reclassified into profit or loss		
(1) Changes in remeasurement on defined benefit plan		
(2) Other comprehensive income that cannot be transferred to profit and loss under equity method		
(3) Fair value change on other investments in equity instruments		
(4) Fair value change on credit risk of the enterprise		
2.Other comprehensive income that will be reclassified into profit or loss		
(1) Other comprehensive income that can be transferred to profit and loss under equity method		
(2) Fair value change on other debt investments		

(3) Amounts of financial assets reclassified into other comprehensive income		
(4) Provision on credit impairment on other debt investments		
(5) Reserves of cash flow hedging		
(6) Translation difference on financial statements denominated in foreign currencies		
(7) Others		
(II) Net other comprehensive income after tax attributable to non-controlling shareholders		
7. Total comprehensive income	191,612,423.86	61,008,648.47
(A) Total comprehensive income attributable to the owners of the parent company	191,531,404.47	61,151,445.55
(B) Total comprehensive income attributable to non-controlling shareholders	81,019.39	-142,797.08
8. Earnings per share:		
(A) Basic earnings per share (RMB/share)	0.50	0.16
(B) Diluted earnings per share (RMB/share)	0.50	0.16

For business combination under common control conducted during the current period, the acquiree achieved a net profit of RMB0.00 before the combination; the acquiree achieved a net profit of RMB0.00 during the previous period.

Person in charge of the Company: Shi Wenling; Person in charge for accounting affairs of the Company: Lu Hongyue; Person in charge of the accounting department: Lu Hongyue

Consolidated cash flow statement

January to September 2025

Prepared by: Beijing Chunlizhengda Medical Instruments Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2025 (January to September)	First three quarters of 2024 (January to September)
1. Cash flows from operating activities:		
Cash receipts from sale of goods and rendering of services	787,304,954.60	704,325,961.65

Net increase in the amounts of deposits from customers and placements from peers		
Net increase in amounts due to central banks		
Net increase in placements from other financial institutions		
Cash received from the premium of original insurance contract		
Net cash received from reinsurance business		
Net increase in policyholder deposits and amount for investment		
Cash received from interest, handling fee and commission		
Net increase in placements from banks and non-bank financial institutions		
Net increase in capital on business repurchased		
Net cash received on securities dealing agency services		
Receipts of tax refund	2,825,763.95	3,949,002.56
Other cash receipts related to operating activities	15,765,417.63	31,276,669.26
Subtotal of cash inflow from operating activities	805,896,136.18	739,551,633.47
Cash payments for goods purchased and services received	298,567,305.53	254,181,935.07
Net increase in loans and advances from customers		
Net increase in amounts deposited in central bank and peers		
Cash payment on compensation payout in original insurance contract		
Net increase in placements with banks and non-bank financial institutions		
Cash payment on interest, handling fee and commission		
Cash payment for policy dividend		
Cash paid to and on behalf of employees	149,971,256.13	195,375,092.18

Taxes paid	29,932,778.50	67,437,773.37
Other cash payments related to operating activities	152,857,751.91	239,836,246.60
Subtotal cash outflow from operating activities	631,329,092.07	756,831,047.22
Net cash flows from operating activities	174,567,044.11	-17,279,413.75
2. Cash flows from investing activities:		
Cash received from disinvestments	744,000,000.00	1,570,000,000.00
Cash received from return on investments	6,619,109.04	12,955,317.80
Net cash received from the disposal of fixed assets, intangible assets and other long-term assets	23,000.00	89,090.12
Net cash received from the disposal of subsidiaries and other business units		
Other cash receipts related to investing activities		
Subtotal of cash inflow from investing activities	750,642,109.04	1,583,044,407.92
Cash paid for acquiring fixed assets, intangible assets and other long-term assets	48,492,401.83	32,216,273.35
Cash payments for investments	880,000,000.00	1,500,000,000.00
Net increase in pledged loans		
Net cash payments for acquisitions of subsidiaries and other business units	2,200,000.00	
Other cash payments related to investing activities		
Subtotal of cash outflow from investing activities	930,692,401.83	1,532,216,273.35
Net cash flows from investing activities	-180,050,292.79	50,828,134.57
3. Cash flows from financing activities:		
Cash received from investments		
Including: Cash received by subsidiaries from non-controlling shareholders' investments		
Cash received from borrowings		
Other cash receipts related to financing activities		

Subtotal of cash inflow from financing activities		
Cash repayment of debts		
Cash paid for distribution of dividends, profits or for interest expenses	18,727,390.80	138,769,585.99
Including: Dividends and profit paid by subsidiaries to non-controlling shareholders		
Other cash payments related to financing activities	8,656,570.63	5,588,314.32
Subtotal of cash outflow from financing activities	27,383,961.43	144,357,900.31
Net cash flows from financing activities	-27,383,961.43	-144,357,900.31
4. Effect of foreign exchange rate changes on cash and cash equivalents	-248,760.77	1,677.48
5. Net increase in cash and cash equivalents	-33,115,970.88	-110,807,502.01
Add: Opening balance of cash and cash equivalents	1,139,017,650.66	1,266,013,075.67
6. Closing balance of cash and cash equivalents	1,105,901,679.78	1,155,205,573.66

Person in charge of the Company: Shi Wenling; Person in charge for accounting affairs of the Company: Lu Hongyue; Person in charge of the accounting department: Lu Hongyue

Adjustments to the financial statements at the beginning of the year of the first implementation due to the first implementation of the new accounting standards or interpretation of accounting standards since 2025

□Applicable √Non applicable

The Board of Directors of Beijing Chunlizhengda Medical Instruments Co., Ltd.*

30 October 2025

** For identification purposes only*